Advertisement

Baxter's VIVIA hemodialysis system lands CE Marking in the European Union with indication for more frequent, extended duration, short daily or nocturnal home high-dose therapy.

Baxter lands CE Mark for VIVIA multi-setting hemodialysis system

Illinois medical device maker Baxter's (NYSE:BAX) won European regulatory approval for its VIVIA hemodialysis system, designed for use in multiple settings and therapy regimens.

The VIVIA system, designed to be operated primarily by a patient, is indicated for use in "more frequent, extended duration, short daily or nocturnal home [high-dose] therapy," Baxter said. VIVIA features touch-screen technology, a graphic interface and animations that guide patients through setup, treatment and cleanup.

Advertisement
Advertisement